ZBH Zimmer Biomet Holdings, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
ZBH Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Medical Devices
Current Price
Live
$87.31
Analyst Target
$102.39
+17.3%
Upside
52W High
$114.44
52W Low
$85.33
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 17, 2026
Market cap
$17.3B
P/E
21.66
ROE
6.4%
Profit margin
10.1%
Debt/Equity
0.65
Dividend yield
1.08%
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
Zimmer Biomet (ZBH) exhibits strong deterministic health with a Piotroski F-Score of 7/9, indicating solid financial stability. However, the absence of an Altman Z-Score limits full solvency risk assessment. The stock trades above its Graham Number of $76.39 at $87.31, reflecting a modest premium, while forward P/E of 10.30 suggests improved earnings expectations. Despite solid revenue growth and insider selling pressure, mixed earnings performance and declining profitability metrics temper bullish sentiment.
Key Strengths
Strong Piotroski F-Score of 7/9 indicates robust financial health and operational efficiency
Revenue growth of 9.70% YoY outpaces sector average of 9.80%, showing competitive momentum
High gross margin of 71.62% reflects pricing power and cost control in the medical devices space
Low debt/equity ratio of 0.65 suggests conservative capital structure and financial flexibility
Current ratio of 2.43 indicates strong short-term liquidity and ability to meet obligations
Key Risks
Earnings growth declining YoY (-5.70%) and Q/Q (-7.30%), signaling potential profitability headwinds
ROE of 6.42% lags significantly behind sector average of 25.54%, indicating suboptimal capital efficiency
Insider selling activity over the past 6 months reflects bearish sentiment from management
Technical trend score of 0/100 indicates strong bearish momentum in price action
Forward P/E compression from current 21.67 to 10.30 implies market expects decelerating earnings growth
AI Fair Value Estimate
Based on comprehensive analysis
$76.39
-12.5% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
56
Moderate
52
48
60
78
40
AI Verdict
Neutral with upside risk if earnings stabilize
Key drivers: Piotroski strength, Revenue growth, Valuation premium to Graham, Insider selling, Declining earnings
Confidence
75%
Value
52/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 10.30 is below current P/E, suggesting valuation improvement
- Price/Sales of 2.16 is reasonable for medical devices sector
Watchpoints
- Current price ($87.31) trades above Graham Number ($76.39), indicating overvaluation on defensive criteria
- P/E of 21.67 is high relative to forward P/E, suggesting earnings risk
Future
48/100
Ref Growth rates
Positives
- Revenue growth of 9.70% YoY is positive
- Most recent Q/Q EPS growth of +50.6% shows potential rebound
Watchpoints
- Earnings growth YoY is -5.70%
- Q/Q earnings growth is -7.30%, indicating near-term weakness
Past
60/100
Ref Historical trends
Positives
- Historical earnings surprises show strong beats in prior years (e.g., +67.4% in 2020)
- Consistent revenue progression over multiple quarters
Watchpoints
- Last 4 quarters beat estimates only 2/4 times
- Average earnings surprise of -1.99% over last 4 quarters indicates weakening performance
Health
78/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 7/9 is strong
- Current ratio of 2.43 and quick ratio of 1.21 indicate solid liquidity
Watchpoints
- Altman Z-Score not available, limiting distress risk analysis
- ROA of 4.33% is low, suggesting inefficient asset utilization
Dividend
40/100
Ref Yield, Payout
Positives
- Payout ratio of 23.82% is sustainable and leaves room for future increases
Watchpoints
- Dividend Strength score of 25/100 indicates weak yield and growth
- Dividend yield of 1.08% is below sector average and not a major attraction
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$87.31
Analyst Target
$102.39
Upside/Downside
+17.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ZBH and closest competitors.
Updated 2026-01-16
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ZBH
Zimmer Biomet Holdings, Inc.
Primary
|
-41.4% | -27.1% | -19.1% | -5.8% | -4.4% | -6.0% |
|
HOLX
Hologic, Inc.
Peer
|
-1.3% | -5.6% | +7.2% | +17.2% | +0.1% | +0.1% |
|
MRNA
Moderna, Inc.
Peer
|
-66.5% | -78.1% | +23.9% | +33.8% | +37.1% | +21.9% |
|
BBIO
BridgeBio Pharma, Inc.
Peer
|
+18.4% | +720.5% | +110.0% | +68.2% | +1.8% | +2.1% |
|
ASND
Ascendis Pharma A/S
Peer
|
+48.1% | +92.3% | +84.6% | +40.6% | +10.6% | +14.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
21.66
Forward P/E
10.3
PEG Ratio
N/A
P/B Ratio
1.36
P/S Ratio
2.16
EV/Revenue
3.03
EV/EBITDA
9.18
Market Cap
$17.3B
Profitability
Profit margins and return metrics
Profit Margin
10.05%
Operating Margin
17.0%
Gross Margin
71.62%
ROE
6.42%
ROA
4.33%
Growth
Revenue and earnings growth rates
Revenue Growth
+9.7%
Earnings Growth
-5.7%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-7.3%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.65
Moderate
Current Ratio
2.43
Strong
Quick Ratio
1.21
Good
Cash/Share
$6.59
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-10
$N/A
2025-11-05
$1.16
+24.6% surprise
2025-08-07
$0.77
-34.7% surprise
2025-05-05
$0.91
+4.2% surprise
Healthcare Sector Comparison
Comparing ZBH against 147 companies in the Healthcare sector
(9 bullish, 56 neutral, 82 bearish)
P/E Ratio
21.66
This Stock
vs
164.76
Sector Avg
-86.9%
(Discount)
Return on Equity (ROE)
6.42%
This Stock
vs
-53.48%
Sector Avg
-112.0%
(Below Avg)
Profit Margin
10.05%
This Stock
vs
-20.64%
Sector Avg
-148.7%
(Weaker)
Debt to Equity
0.65
This Stock
vs
6.19
Sector Avg
-89.6%
(Less Debt)
Revenue Growth
9.7%
This Stock
vs
137.13%
Sector Avg
-92.9%
(Slower)
Current Ratio
2.43
This Stock
vs
3.37
Sector Avg
-28.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ZBH
Zimmer Biomet Holdings, Inc.
|
NEUTRAL | $17.3B | 21.66 | 6.4% | 10.1% | $87.31 | |
|
HOLX
Hologic, Inc.
|
NEUTRAL | $16.73B | 30.11 | 11.1% | 13.8% | $74.98 | |
|
MRNA
Moderna, Inc.
|
BEARISH | $16.34B | - | -29.3% | -139.6% | $41.83 | |
|
BBIO
BridgeBio Pharma, Inc.
|
BEARISH | $14.92B | - | -% | -225.3% | $77.87 | |
|
ASND
Ascendis Pharma A/S
|
NEUTRAL | $14.38B | - | -% | -36.0% | $235.39 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-28 | WINKLER LORI | Officer | Stock Award | 179 | - |
| 2025-11-10 | UPADHYAY SUKETU P | Chief Financial Officer | Stock Award | 10,632 | - |
| 2025-09-11 | YI SANG | Officer | Sale | 1,200 | $124,302 |
| 2025-09-08 | WINKLER LORI | Officer | Sale | 1,500 | $156,225 |
| 2025-08-29 | STELLATO PAUL A | Officer | Stock Award | 1,281 | - |
| 2025-08-18 | WINKLER LORI | Officer | Sale | 1,500 | $153,735 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
23 analysts
Bernstein
2026-01-09
Market Perform
Market Perform
BTIG
2026-01-08
Buy
Buy
Evercore ISI Group
2026-01-05
In-Line
Outperform
Baird
2025-12-16
Outperform
Neutral
Citigroup
2025-12-11
Neutral
Neutral
Canaccord Genuity
2025-11-10
Hold
Hold
UBS
2025-11-06
Sell
Sell
RBC Capital
2025-11-06
Outperform
Outperform
Barclays
2025-11-06
Underweight
Underweight
JP Morgan
2025-11-06
Overweight
Neutral
Past News Coverage
Recent headlines mentioning ZBH from our newsroom.
Newest → oldest
No matching news yet.